Globe Newswire07.21.21
Relievant Medsystems, a privately held medical device company transforming the treatment of chronic low back pain (CLBP), has appointed Tyler Binney as president and CEO. Binney will also join Relievant’s Board of Directors. Arthur Taylor, who previously held the CEO position on an interim basis, will return to his role on the Board of Directors.
“Tyler is a proven leader and has a long and successful history of bringing disruptive medical devices to market. We look forward to leveraging his experience accelerating growth through commercial execution, product innovation, and the building of strong, integrated teams,” said Richard Mott, executive board chairman of Relievant. “With an unparalleled level of clinical evidence supporting Intracept’s position in the CLBP care pathway and a Category I CPT code effective in January 2022, Relievant is poised for its next phase of growth—and Tyler brings the right blend of experience and expertise to lead the company at this important stage.”
Binney brings more than 20 years of medical device leadership experience. He most recently served as president and general manager of Interventional Urology at Teleflex. He had previously served as vice president of Sales at NeoTract Inc., which was acquired by Teleflex in 2017. Prior to his tenure at NeoTract, he served in multiple leadership roles in sales and marketing within two business units at Johnson & Johnson (Acclarent and Cordis).
“I am excited to join the Relievant team at this important time, with a rapidly growing number of physicians recognizing that the Intracept procedure fills a well-established gap in the CLBP care pathway,” said Binney. “The Intracept procedure has been shown to deliver long-lasting improvements in pain and function for CLBP patients, with an objective biomarker that helps physicians identify those who may benefit from the procedure. I am excited to lead this team forward, continuing the successful commercialization achieved to date.”
The Intracept procedure is cleared by the U.S. Food and Drug Administration and available across the United States.
“Tyler is a proven leader and has a long and successful history of bringing disruptive medical devices to market. We look forward to leveraging his experience accelerating growth through commercial execution, product innovation, and the building of strong, integrated teams,” said Richard Mott, executive board chairman of Relievant. “With an unparalleled level of clinical evidence supporting Intracept’s position in the CLBP care pathway and a Category I CPT code effective in January 2022, Relievant is poised for its next phase of growth—and Tyler brings the right blend of experience and expertise to lead the company at this important stage.”
Binney brings more than 20 years of medical device leadership experience. He most recently served as president and general manager of Interventional Urology at Teleflex. He had previously served as vice president of Sales at NeoTract Inc., which was acquired by Teleflex in 2017. Prior to his tenure at NeoTract, he served in multiple leadership roles in sales and marketing within two business units at Johnson & Johnson (Acclarent and Cordis).
“I am excited to join the Relievant team at this important time, with a rapidly growing number of physicians recognizing that the Intracept procedure fills a well-established gap in the CLBP care pathway,” said Binney. “The Intracept procedure has been shown to deliver long-lasting improvements in pain and function for CLBP patients, with an objective biomarker that helps physicians identify those who may benefit from the procedure. I am excited to lead this team forward, continuing the successful commercialization achieved to date.”
The Intracept procedure is cleared by the U.S. Food and Drug Administration and available across the United States.